<DOC>
	<DOCNO>NCT02189733</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetic characteristic demonstrate bioequivalence reconstitute new lyophilized formulation caplacizumab subcutaneous ( s.c. ) injection compare equal nominal s.c. dose reference liquid formulation caplacizumab . The secondary objective study compare safety tolerability , pharmacodynamic parameter new formulation reference formulation .</brief_summary>
	<brief_title>Bioequivalence Liquid Reconstituted Lyophilized Subcutaneous Formulations Caplacizumab .</brief_title>
	<detailed_description />
	<criteria>Male Caucasians age 18 55 year , inclusive . Body weight 55 100 kg body mass index ( BMI ) 18.5 30.0 , extremes include . Coagulation bleed diathesis variable ( define protocol ) within normal range screen Day 1 . Others define protocol . History presence disease kidneys and/or heart , lung , liver , skin , endocrine organ condition know interfere absorption , distribution , metabolism excretion drug . History and/or sign symptom indicate current abnormal hemostasis blood dyscrasia . Others define protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>